Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate

Brazilian Journal of Medical and Biological Research

Volumn 38, Issue 12, 2005, Pages 1879-1883

  Schettini, D A ^a   Costa Val, A P ^a   Souza, L F ^a   Demicheli, C ^a   Rocha, O G F ^b   Melo, M N ^a   Michalick, M S M ^a   Frezard F ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FUNDAÇÃO CENTRO TECNOLÓGICO DE MINAS GERAIS   (Brazil)

Author keywords

Bone marrow; Dogs; Leishmaniasis; Liposome; Meglumine antimoniate; Pharmacokinetics

Indexed keywords

ANTIMONY; LIPOSOME; MEGLUMINE ANTIMONATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BONE MARROW; CONTROLLED STUDY; DOG; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; ENCAPSULATION; LEISHMANIA CHAGASI; MALE; NONHUMAN; VISCERAL LEISHMANIASIS;

ANIMALIA; CANIS FAMILIARIS; LEISHMANIA DONOVANI CHAGASI;

EID: 30544454425     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2005001200017     Document Type: Article

References (11)

1. Alexander A & Russel DG (1992). The interaction of Leishmania species with macrophages. Advances in Parasitology, 31: 175-254.
2. Marsden PD (1985). Pentavalent antimonials: old drug for new diseases. Revista da Sociedade Brasileira de Medicina Tropical, 18: 187-198.
3. Alvar J, Molina R, San Andrés M et al. (1994). Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy. Annals of Tropical Medicine and Parasitology, 88: 371-378.
4. Frézard F, Michalick MSM, Soares CF et al. (2000). Novel methods for the encapsulation of meglumine antimoniate in liposomes. Brazilian Journal of Medical and Biological Research, 33: 841-846.
5. Schettini DA, Costa Val AP, Souza LF et al. (2003). Biodistribution of liposome-encapsulated antimony in dogs. Brazilian Journal of Medical and Biological Research, 36: 269-272.
6. Demicheli C, Ochoa R, Lula IS et al. (2003). Pentavalent organoantimonial derivatives: two simple and efficient synthetic methods for meglumine antimonate. Applied Organometallic Chemistry, 17:226-231.
7. Roura X, Sanchez A & Ferrer L (1999). Diagnosis of canine leishmaniasis by a polymerase chain reaction technique. Veterinary Record, 144: 262-264.
8. Collins M, Carter KC, Baillie AJ et al. (1993). The distribution of free and non-ionic vesicular sodium stibogluconate in the dog. Journal of Drug Targeting, 1: 133-142.
9. Carter KC, Dolan TF, Alexander J et al. (1989). Visceral leishmaniasis: drug carrier characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice. Journal of Pharmacy and Pharmacology, 41: 87-91.
10. Chulay JD, Fleckenstein L & Smith DH (1988). Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Transactions of the Royal Society of Tropical Medicine and Hygiene, 82: 69-72.
11. Valladares JE, Riera C, Gonzalez- Ensenyat P et al. (2001). Long term improvement in the treatment of canine leishmaniasis using an antimony liposomal formulation. Veterinary Parasitology, 97: 15-21.